Figures & data
Scheme 1. (a) Synthesis of Pt(IV)-COOH compound and cisplatin release after reduction in the cell. (b) Synthesis process of Pt(IV)-MeNPs.
Figure 1. (a) Size distribution determined by DLS of NH2-MeNPs and Pt(IV)-MeNPs. (b) TEM image of NH2-MeNPs. (c) UV–vis absorption spectra of synthesized NH2-MeNPs. (d) Photothermal heating curves of synthesized NH2-MeNP solution with varied concentrations irradiated under laser exposure at a power density of 0.5 W/cm2.
Figure 2. (a) Pt(II) release profiles of Pt(IV)-MeNPs in PBS (pH = 7.4) with or without 0.1 mM AsA solution. (b) Chemical reduction of Pt(II) from the Pt(IV)-MeNP in PBS buffer (pH 7.4) by 0.1 mM AsA with or without NIR laser irradiation (808 nm, 0.5 W/cm2, 15, 30 and 120 min, respectively). *p < .05 and **p < .01 was calculated by Student's t-test.
Figure 3. In vitro antitumour activity against prostate cancer cells. The cytotoxicity of Pt(IV)-MeNPs, Pt(IV)-COOH, Cisplatin and MeNPs on PC3 (a), DU145 (b) and LnCap (c) cells. (d) The photothermal effect of prostate cancer cells treated by Pt(IV)-MeNPs with NIR, Pt(IV)-MeNPs without NIR or PBS with NIR, respectively. The power density of irradiation was 0.5 W/cm2 for 15 min.
Figure 4. Cellular uptake of various drugs by PC3 cells at 4 h determined by ICP-MS. The initial platinum concentration of all drugs was 5 μM. Cellular uptake was expressed in the unit of (ng Pt/mg proteins).
Figure 5. In vivo chemo-photothermal therapy treatment of tumour by using Pt(IV)-MeNPs. (a) The blood circulation of Pt(IV)-MeNPs. (b) The biodistribution of the tumour and main organs of PC3 xenograft tumour-bearing nude mice sacrificed at 24 h post-injection of Pt(IV)-MeNPs or cisplatin at 24 h post-injection. (c) The tumour volume evolution of mice in different groups during the therapeutic period. (d) Photographs of the excised tumours of mice after sacrifice. (e) Curves of tumour temperature increase after NIR irradiation for the groups treated with Pt(IV)-MeNPs + NIR or NIR only. (f) The body weight changes of mice during the therapeutic period. *p < .05 and **p < .01 were calculated by Student’s t-test.
